Bicalutamide and Ridaforolimus in Men With Prostate Cancer (MK-8669-002)
This study will look to see if the combination of ridaforolimus and bicalutamide works better than placebo and bicalutamide in men with prostate cancer.
Prostate Cancer
DRUG: ridaforolimus (MK8669)|DRUG: Comparator: Placebo|DRUG: open-label ridaforolimus (MK8669)
30% Prostate specific antigen (PSA) decline within 12 weeks, 12 weeks|Number of dose limiting toxicities (DLTs), Day 1 to Day 35
Prostate specific antigen (PSA) response rate, 12 weeks|Number of patients with progression free survival (PFS), 12 weeks|Time to prostate specific antigen (PSA) progression, 12 weeks|Pharmacokinetics Maximum Concentration (Cmax), Time to Maximum Plasma Concentration (Tmax), Area Under the Concentration Versus Time Curve (AUC) of Ridaforolimus, 30 Minutes to 24 hour postdose
Ridaforolimus (MK8669/AP23573) was also known as deforolimus until May 2009.